Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Sumatriptan Succinate Articles

FDA YEAR-END APPROVALS FOR 1993

10 January 1994

EUROPE STOCK COMMENT

10 January 1994

ANALYSTS FORECAST FDA YEAR-END APPROVALS

13 December 1993

GLAXO REAFFIRMS COMMITMENT TO R&D

6 December 1993

STRONG PERFORMANCE FROM GLAXO, AND ZANTAC

13 September 1993

US DRUGSTORE AUDIT DATA FOR JULY

6 September 1993

WILL THERE BE MORE FLEXIBILITY AT GLAXO UNDER SYKES?

28 June 1993

GLAXO'S SINGAPORE PLANT SET FOR 1994

15 February 1993

ANALYST TIPS GLAXO FOR CONTINUED SUCCESS

15 February 1993

FDA APPROVES 26 NEWDRUGS IN 1992

25 January 1993

IMITREX SLOW TO GROW, SAY ANALYSTS

18 January 1993

FDA YEAR-END DRUG APPROVALS ROLL-OUT

4 January 1993

UK FIRMS BOOSTED BY YEAR-END US APPROVALS

4 January 1993

GLAXO'S IMITREX GETS FDA BACKING IN USA

14 December 1992

LONDON STOCK COMMENT

14 December 1992

US PRICE MODERATION "VARIES BY COMPANY"

3 August 1992

US PRICE MODERATION "VARIES BY COMPANY"

3 August 1992

GLAXO PROSPECTS GLOOM: FACT OR FICTION?

3 August 1992

GLAXO INCREASES CNS EMPHASIS IN USA

13 January 1992

Showing 101-119 of 119 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Pfizer to split-off remaining 80% interest in Zoetis
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Pfizer to split-off remaining 80% interest in Zoetis

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS